🔗 Share this article

While America proceeds with sweeping revisions to its immunization guidelines, a particular individual has emerged unexpectedly: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who rose to prominence by expressing skepticism about Covid shots in the pandemic and has concentrated on possible fatalities after COVID-19 immunization in her brief position at the US Food and Drug Administration (FDA).

Planned Shifts to Childhood Immunization Program

Public health authorities were set to unveil sweeping changes to the pediatric vaccination calendar earlier this month, bringing the US with Denmark’s immunization schedule, sources say – a significant shift that would put the US out of step with a large portion of the international standard with no evidence for public health gain. The announcement has been delayed until the new year.

Instead of the director of the vaccine center, Tracy Beth Høeg is set to present at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth person to lead the division this calendar year.

Consolidating Power at the FDA

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad strengthen their influence at the regulatory agency – and it points to a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for ending specific pediatric shot schedules in the US so as to align more similar to Denmark's approach, a country with universal health coverage and a number of inhabitants roughly the population of the state of Wisconsin.

In her initial comments, she has kept her attention on immunizations – typically the domain of Prasad, chief of the FDA’s CBER – instead of medication approval.

Questions Over Background

Dr. Høeg has no obvious background in pharmaceutical research, regulation or management, which has been typical for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a senior adviser to the FDA chief and CBER since spring.

“She doesn’t seem to have any of the qualifications” for running the CDER, said a neurologist and psychiatrist. “She lacks experience running a scientific study. She has no expertise in managing a large organization. She is not an expert in pharmaceutical oversight.”

Past directors of the center would “grasp laws and regulations and the science of medication creation”, commented Janet Woodcock. “Objectively, she lacks the sort of resume that previous people who headed the center have had.”

The drug center has an enormous range of responsibilities at the agency, Woodcock emphasized.

“The public just pays attention on the innovative therapies, but the off-patent medication office clears thousands of generic drugs. There is also a biologic copycat branch, non-prescription drug unit and so forth, and each of these have to be looked after,” Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant leadership aspect to the job, which manages over 5,000 employees. “It is a huge administrative position, if you execute it properly,” the former official concluded.

Agency Reaction and Disputed Policies

Regarding concerns about Høeg’s qualifications and whether this appointment represents more teamwork among FDA leaders on immunizations, a press secretary stated that the “questions stem from inaccurate premises”.

“Her experience is consistent with the functions of her position,” the official explained, noting the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

As the temporary head, Høeg assumes responsibility for the agency head's new expedited review system, a contentious rapid medication authorization process that allegedly concerned her predecessors. “By what process are these drugs being selected for this voucher program? Who makes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the regulatory body right now.”

Broadly speaking, he remarked, “the agency looks to be trending towards laxer regulations of pharmaceuticals, with the exception of immunizations.”

Public Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a clearer, if problematic, past, some experts said. She authored a research paper using unconfirmed volunteer-provided data to estimate the frequency of heart inflammation after Covid vaccination. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the incoming administration included revising rules for novel immunizations and ending “non-essential” vaccines, she said post-election on a podcast. At the agency, Dr. Høeg has allegedly suggested preventing young men from getting Covid vaccinations.

“She is an thorough true believer who starts off with her preconceived notions and works backwards to accommodate the data in a very disingenuous, fraudulent way,” Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of other skeptics, {like|